Altus Wealth Group’s Altimmune ALT Stock Holding History

Altus Wealth Group’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-900	Closed	-$10K	–	188
2020 Q4	$10K	Buy	+900	New	+$10.6K	0.01%	516

Other funds holding ALT

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CCM

CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Altus Wealth Group's ALT Position: Q1 2021 in Review

Altus Wealth Group sold out of Altimmune (ALT) in Q1 2021, closing a stake of 900 shares — an estimated $10K sold.

Altus Wealth Group first reported a position in ALT in Q4 2020 and held it in 1 quarter. The position peaked at $10K in Q4 2020. 96 funds tracked by Wall St. Rank hold ALT as of Q1 2021.

Altus Wealth Group reported no remaining Altimmune position as of Q1 2021 after selling out during the quarter.
Altus Wealth Group sold 900 Altimmune shares in Q1 2021, an estimated $10K.
Altus Wealth Group first reported a position in Altimmune in Q4 2020 and held it in 1 quarter.
Altus Wealth Group's Altimmune position peaked at $10K in Q4 2020.
96 funds tracked by Wall St. Rank held Altimmune as of Q1 2021.

Based on Altus Wealth Group's 13F filing for Q1 2021, filed 14 May 2021.